ANTHONY CLARK: Second opinion on Ascendis
Private investors using investigative work and patience can find profits at Ascendis
I’ve been covering small-to mid-cap stocks for nearly 40 years. They say the market is efficient and the market knows everything. But even in 2020, as it was when I started analysing stock in the 1980s, the market does not know everything. It misses much, which is why an analyst has to be much more of a detective with smaller stocks.The market is also impatient. Here are some insights to these comments and how private investors with some basic investigative work and patience can often outgun the big boys.Popular private client micro-cap stock Ascendis is one such stock. This R295m heavily indebted health-care and pharmaceutical stock is barely followed. Whenever I comment on my Twitter page on it I get hordes of queries.In year-end results to September the year-on-year losses fell from 99.9c a share to a loss of 6c a share. It will move back into positive earnings in financial 2021.The market wanted more despite the sharp reduction in normalised losses. The share price declined 20% ...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.